Else Nutrition Signs MOU for State-of-the-Art Infant Nutrition Facility

Else Nutrition

Since Rich first profiled Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQB:BABYF), the stock has doubled in value. Anyone who invested on Rich’s initial recommendation has seen shares climb from $0.34 a pop to $0.70.

One of the reasons this stock continues to rally is that Else routinely announces exciting news. As the company approaches the launch of its patented, 100% plant-based infant formula, it has more news to tout today.

“Else Nutrition reminds me of Tesla—it’s another company that’s changing the world,” says Rich. “This is one of the biggest plays for our community, and they’ve got more breaking news.”

Else Signs Production MOU with Leading Organic Baby Formula Producer

On February 4, Else Nutrition announced that it signed a 5-year production Memorandum of Understanding (MOU) with a leading US-based organic baby formula producer.

As a result of the MOU, the company will operate a State-Of-The-Art Infant Nutrition Facility. At this facility, it will produce its proprietary powder for infant, toddler formula and children’s nutritional drinks.

Enter Your E-mail Address To Subscribe

* indicates required
 

The company will also invest in a dedicated packaging and manufacturing line for its products. It will invest C$500,000 to bring this to fruition.

Else Nutrition CEO Hamutal Yitzhak said of the deal:

“After a rigorous selection process, we are delighted to enter into this production MOU, as it will allow us to ensure the highest quality and purity standards for Else formula. This world-class facility provides for hands-on monitoring of each batch, ensuring increased testing accuracy and the highest quality in finished products. Having such high-caliber, long-term production in the U.S. ensures we can efficiently meet future demand in this key global market while adhering to our strict quality standards.”

Else Nutrition’s first products will launch in the US in Q2 2020. This will be its plant-based, non-dairy, non-soy toddler formula and children’s nutritional drinks.

“This launch is right around the corner,” explains Rich. “We haven’t even started doing sales yet! What do you think is going to happen when they start sales? I predict BABY goes to $1.00.”

Else Nutrition’s Strong Patents and Expanding Portfolio

Else enjoys very strong IP protection. This will allow it to fully capitalize on being the first mover in the plant-based infant formula space.

BABY’s formula has received patents in 20 countries, including the United States, Australia, Japan, Ukraine, Israel, Russia, South Africa, and New Zealand. The company also has a further 50+ patents pending.

Two weeks ago, Else received a notice of allowance from the US Patent Office to extend its existing patents to cover the adult market for malnutrition.

This means the company’s proprietary formula can be marketed to adults who have specific malnutrition-related conditions. Conditions like this include lean body mass and declining basal metabolic rates.

Else is ready to disrupt the plant-based foods market. Data from the Plant Based Foods Association and The Good Food Institute reveals that sales of plant-based foods grew 11 percent across America last year. The US market for 2019 is valued at $4.5 billion and is likely to continue to grow at a similar rate.

What do you think of Else Nutrition? Will the plant-based trend be a game-changer for stocks like BABY? Let us know your thoughts!

Featured image: DepotsitPhotos © Komokvm

Please See Disclaimer

If You Liked This Article Click To Share


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on richtvlive.com should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.